Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
21 June 2019Website:
http://www.artelobio.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 24 Oct 2024 21:29:32 GMTDividend
Analysts recommendations
Institutional Ownership
ARTL Latest News
SOLANA BEACH, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today reported its financial and operating results for the three months ended June 30, 2024 and provided a business update.
Multiple studies confirm ART12.11's superior advantages as a product candidate for the treatment of anxiety related disorders Multiple studies confirm ART12.11's superior advantages as a product candidate for the treatment of anxiety related disorders
New data demonstrates that ART26.12 works by activating multiple receptors implicated in pain signaling and is able to broadly modify lipids in chemotherapy-induced peripheral neuropathy New data demonstrates that ART26.12 works by activating multiple receptors implicated in pain signaling and is able to broadly modify lipids in chemotherapy-induced peripheral neuropathy
ART12.11, a Novel and Patented Cocrystal of Cannabidiol, Improves Bioavailability and Efficacy of CBD ART12.11, a Novel and Patented Cocrystal of Cannabidiol, Improves Bioavailability and Efficacy of CBD
What type of business is Artelo Biosciences?
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
What sector is Artelo Biosciences in?
Artelo Biosciences is in the Healthcare sector
What industry is Artelo Biosciences in?
Artelo Biosciences is in the Biotechnology industry
What country is Artelo Biosciences from?
Artelo Biosciences is headquartered in United States
When did Artelo Biosciences go public?
Artelo Biosciences initial public offering (IPO) was on 21 June 2019
What is Artelo Biosciences website?
https://www.artelobio.com
Is Artelo Biosciences in the S&P 500?
No, Artelo Biosciences is not included in the S&P 500 index
Is Artelo Biosciences in the NASDAQ 100?
No, Artelo Biosciences is not included in the NASDAQ 100 index
Is Artelo Biosciences in the Dow Jones?
No, Artelo Biosciences is not included in the Dow Jones index
When was Artelo Biosciences the previous earnings report?
No data
When does Artelo Biosciences earnings report?
Next earnings report date is not announced yet